These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29739080)

  • 1. Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma.
    Meddour Y; Rahali MC; Belakehal SE; Ardjoun FZ; Chaib S; Djidjik R
    Clin Lab; 2018 Apr; 64(4):551-558. PubMed ID: 29739080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains.
    Xu Y; Sui W; Deng S; An G; Wang Y; Xie Z; Yao H; Zhu G; Zou D; Qi J; Hao M; Zhao Y; Wang J; Chen T; Qiu L
    Leuk Lymphoma; 2013 Jan; 54(1):123-32. PubMed ID: 22712834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
    García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
    PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma.
    Guo Z; Li H; Geng Y; Cui J; Tang N; Li D
    Am J Med Sci; 2018 Apr; 355(4):350-356. PubMed ID: 29661348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
    van Rhee F; Bolejack V; Hollmig K; Pineda-Roman M; Anaissie E; Epstein J; Shaughnessy JD; Zangari M; Tricot G; Mohiuddin A; Alsayed Y; Woods G; Crowley J; Barlogie B
    Blood; 2007 Aug; 110(3):827-32. PubMed ID: 17416735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.
    Yağcı M; Karakaya F; Suyanı E; Haznedar R
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation and comparison of prognostic value of serum free light chain ratio/difference in patients with newly diagnosed multiple myeloma].
    Li L; Jiang H; Fu WJ; Du J; He HY; Lu J; An R; He J; Zhang H; Zhao YY; Wu H; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):321-326. PubMed ID: 31104445
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic Value of Serum Free Light Chain in Multiple Myeloma.
    El Naggar AA; El-Naggar M; Mokhamer el-H; Avad MW
    Egypt J Immunol; 2015; 22(1):69-78. PubMed ID: 26415374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.
    Barbee MS; Nooka A; Kaufman JL; Kim S; Chen Z; Heffner LT; Lonial S; Harvey RD
    Cancer; 2015 Mar; 121(6):853-62. PubMed ID: 25377852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.
    Tacchetti P; Cavo M; Rocchi S; Pezzi A; Pantani L; Brioli A; Testoni N; Terragna C; Zannetti BA; Mancuso K; Marzocchi G; Borsi E; Martello M; Rizzello I; Zamagni E
    Leuk Lymphoma; 2016 Sep; 57(9):2058-64. PubMed ID: 26763357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.
    Lopez-Anglada L; Cueto-Felgueroso C; Rosiñol L; Oriol A; Teruel AI; Lopez de la Guia A; Bengoechea E; Palomera L; de Arriba F; Hernandez JM; Granell M; Peñalver FJ; Garcia-Sanz R; Besalduch J; Gonzalez Y; Martinez RB; Hernandez MT; Gutierrez NC; Puerta P; Valeri A; Paiva B; Blade J; Mateos MV; San Miguel J; Lahuerta JJ; Martinez-Lopez J;
    PLoS One; 2018; 13(9):e0203392. PubMed ID: 30192814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests.
    Heaney JLJ; Campbell JP; Griffin AE; Birtwistle J; Shemar M; Child JA; Gregory WM; Cairns DA; Morgan G; Jackson G; Drayson MT
    Br J Haematol; 2017 Jul; 178(2):220-230. PubMed ID: 28573706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of Serum Free Light Chain on Renal Function and Prognosis in Patients with Newly Diagnosed Multiple Myeloma].
    Chen XD; Luo XF; Zu YP; Ye H; Li LL; Chen QL; Xie WZ; Yang T; Hu JD; Wei LX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Dec; 27(6):1862-1868. PubMed ID: 31839051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
    Iwama K; Chihara D; Tsuda K; Ugai T; Sugihara H; Nishida Y; Yamakura M; Takeuchi M; Matsue K
    Eur J Haematol; 2013 Feb; 90(2):134-41. PubMed ID: 23210517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of serum free light chain in patients with multiple myeloma].
    Zhang SS; Wu S; Qu XY; Xu J; Liu P; Lu H; Wu HX; Xu JR; Li JY; Chen LJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):930-5. PubMed ID: 23998588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust Reference Intervals for Serum Kappa and Lambda Free Light Chains from a Multi Centre Study Population from Hyderabad, India: Myeloma Diagnostic Implications.
    Mohammed N; Chandran PA; Kandregula M; Mattaparthi RD; Gundeti S; Volturi J; Darapuneni R; Raju SB; Dattatreya PS
    Asian Pac J Cancer Prev; 2016; 17(5):2605-10. PubMed ID: 27268638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Test of Serum Free Light Chain and Its Clinical Significance in Light Chain Multiple Myeloma].
    Song P; An ZM; Zhou XG; Li F; Wang LP; Zhao Q; Yu YP; Zhai YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1357-61. PubMed ID: 26524037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of Serum Free Light Chain Ratio and Normalization Ratio after Treatment on Diagnosis and Prognosis of Patients with Newly Diagnosed Multiple Myeloma].
    Li ZQ; Tian WW; Guo YF; Ma LM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1245-1250. PubMed ID: 32798406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The Value of sFLC and Serum Calcium in the Diagnosis and Prognosis of Multiple Myeloma Patients].
    Pei XH; Zhang LN; Zhou P; Wang TB; Lian C; Zhang P; Lei PC; Zhu ZM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):794-798. PubMed ID: 38926969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy.
    Alhaj Moustafa M; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Hwa YL; Dingli D; Kapoor P; Hayman SR; Lust JA; Kyle RA; Kumar SK
    Leukemia; 2015 Oct; 29(10):2033-8. PubMed ID: 25962523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.